13
Participants
Start Date
January 31, 2011
Primary Completion Date
September 30, 2014
Study Completion Date
June 30, 2015
Eculizumab
Weekly treatment with eculizumab (600 mg) via IV infusion for 4 doses followed the next week by eculizumab (900 mg) IV infusion and maintenance treatment with Eculizumab (900 mg) via IV infusion every other week for 21 weeks
Department of Hematology, University Hospital Essen, Essen
Collaborators (1)
Alexion Pharmaceuticals, Inc.
INDUSTRY
University Hospital, Essen
OTHER